Cliff Asness's HRTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 641,587 shares of Heron Therapeutics, Inc. (HRTX) worth $513,334, representing 0.00% of the portfolio. First purchased in 2014-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in HRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 1.87 M shares. Largest reduction occurred in Q4 2025, reducing 1.56 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Heron Therapeutics (HRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Heron Therapeutics (HRTX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +265,287 | Add 70.50% | 641,587 | $0.80 |
| Q4 2025 | -1.56 M | Reduce 80.57% | 376,300 | $1.30 |
| Q3 2025 | +1.87 M | Add 3036.39% | 1.94 M | $1.26 |
| Q2 2025 | +34,440 | Add 126.11% | 61,749 | $2.07 |
| Q1 2025 | -187,648 | Reduce 87.30% | 27,309 | $2.20 |
| Q4 2024 | -685,150 | Reduce 76.12% | 214,957 | $1.53 |
| Q3 2024 | +292,972 | Add 48.25% | 900,107 | $1.99 |
| Q2 2024 | +568,238 | Add 1460.88% | 607,135 | $3.50 |
| Q1 2024 | +2,042 | Add 5.54% | 38,897 | $2.77 |
| Q4 2023 | -85,912 | Reduce 69.98% | 36,855 | $1.70 |
| Q3 2023 | -25,184 | Reduce 17.02% | 122,767 | $1.03 |
| Q2 2023 | +6,874 | Add 4.87% | 147,951 | $1.16 |
| Q1 2023 | +89,717 | Add 174.68% | 141,077 | $1.51 |
| Q4 2022 | -1,908 | Reduce 3.58% | 51,360 | $2.50 |
| Q3 2022 | +53,268 | New Buy | 53,268 | $4.22 |
| Q2 2019 | -13,202 | Sold Out | 0 | $0.00 |
| Q1 2019 | +13,202 | New Buy | 13,202 | $24.47 |
| Q3 2014 | -75,000 | Sold Out | 0 | $0.00 |
| Q2 2014 | +75,000 | New Buy | 75,000 | $12.32 |
Cliff Asness's Heron Therapeutics Investment FAQs
Cliff Asness first purchased Heron Therapeutics, Inc. (HRTX) in Q2 2014, acquiring 75,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Heron Therapeutics, Inc. (HRTX) for 19 quarters since Q2 2014.
Cliff Asness's largest addition to Heron Therapeutics, Inc. (HRTX) was in Q3 2025, adding 1,936,689 shares worth $2.44 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 641,587 shares of Heron Therapeutics, Inc. (HRTX), valued at approximately $513,334.
As of the Q1 2026 filing, Heron Therapeutics, Inc. (HRTX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Heron Therapeutics, Inc. (HRTX) was 1,936,689 shares, as reported at the end of Q3 2025.